RESUMO
The "bench to bedside" (BTB) paradigm of translational medicine (TM) assumes that medical progress emanates from basic science discoveries transforming clinical therapeutic models. However, a recent report found that most published medical research is false due, among other factors, to small samples, inherent bias and inappropriate statistical applications. Translation-blocking factors include the validity (or lack thereof) of the underlying pathophysiological constructs and related therapeutic paradigms and adherence to faulty traditional beliefs. Empirical discoveries have also led to major therapeutic advances, but scientific dogma has retrospectively retranslated these into the BTB paradigm. A review of the history of intravenous (I.V.) and oral therapy for cholera and NDDs illustrates some fallacies of the BTB model and highlights pitfalls blocking translational and transformative progress, and retro-translational factors, including programmatic modifications of therapeutic advances contradicting therapeutic paradigms and medical economic factors promoting more expensive and profitable medical applications inaccessible to resource-limited environments.
Assuntos
Ira , Cólera/história , Cólera/microbiologia , História Medieval , Humanos , Medicina ArábicaAssuntos
Cólera/prevenção & controle , Zinco/administração & dosagem , Administração Oral , Toxina da Cólera/antagonistas & inibidores , Suplementos Nutricionais , Humanos , Absorção Intestinal , Soluções para Reidratação/administração & dosagem , Soluções para Reidratação/química , Fatores de Tempo , Zinco/metabolismo , Zinco/farmacologiaAssuntos
Bicarbonatos , Hidratação , Glucose , Cloreto de Potássio , Soluções para Reidratação , Cloreto de Sódio , Bicarbonatos/química , Cólera , Diarreia , Glucose/química , Humanos , Concentração Osmolar , Cloreto de Potássio/química , Soluções para Reidratação/química , Cloreto de Sódio/químicaAssuntos
Química Farmacêutica/normas , Soluções para Reidratação/normas , Adulto , Criança , HumanosRESUMO
The Kiryas Joel community in Monroe, N.Y. was the site of the first clinical trial which proved the protective efficacy of hepatitis A vaccine. The vaccine used was VAQTA J. Med. Virol (hepatitis A vaccine, inactivated). In the 9 years since the trial ended vaccination of infants reaching 2 years of age has continued along with monitoring for hepatitis A cases. The prevaccine pattern of frequent outbreaks has converted to a sustained pattern of no outbreaks, despite sporadic introduction of hepatitis A into the community in nonvaccinees. Community use of VAQTA in children 2 years of age and older has proven capable of providing long-term prevention of hepatitis A outbreaks in a formerly frequently affected community despite prolonged sporadic introduction of the virus.
Assuntos
Vacinas contra Hepatite A/administração & dosagem , Adolescente , Adulto , Criança , Pré-Escolar , Surtos de Doenças , Seguimentos , Hepatite A/epidemiologia , Hepatite A/imunologia , Hepatite A/prevenção & controle , Anticorpos Anti-Hepatite A , Anticorpos Anti-Hepatite/sangue , Humanos , New York/epidemiologiaRESUMO
Evidence based vaccinology (EBV) is the identification and use of the best evidence in making and implementing decisions during all of the stages of the life of a vaccine, including pre-licensure vaccine development and post-licensure manufacture and research, and utilization of the vaccine for disease control. Vaccines, unlike most pharmaceuticals, are in a continuous process of development both before and after licensure. Changes in biologics manufacturing technology and changes that vaccines induce in population and disease biology lead to periodic review of regimens (and sometimes dosage) based on changing immunologic data or public perceptions relevant to vaccine safety and effectiveness. EBV includes the use of evidence based medicine (EBM) both in clinical trials and in national disease containment programs. The rationale for EBV is that the highest evidentiary standards are required to maintain a rigorous scientific basis of vaccine quality control in manufacture and to ensure valid determination of vaccine efficacy, field effectiveness and safety profiles (including post-licensure safety monitoring), cost-benefit analyses, and risk:benefit ratios. EBV is increasingly based on statistically validated, clearly defined laboratory, manufacturing, clinical and epidemiological research methods and procedures, codified as good laboratory practices (GLP), good manufacturing practices (GMP), good clinical research practices (GCRP) and in clinical and public health practice (good vaccination practices, GVP). Implementation demands many data-driven decisions made by a spectrum of specialists pre- and post-licensure, and is essential to maintaining public confidence in vaccines.